Cassava Sciences' Alzheimer's drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials. SAVA stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback